The Global Alzheimer’s Platform Foundation (GAP) is releasing the first results from the Bio-Hermes-001 Study. This study of more than 1,000 community-based participants from throughout the U.S. compared the results of blood and digital biomarkers with brain amyloid PET scans or cerebrospinal fluid assays.